CCR3 and Choroidal Neovascularization

Yiwen Li, Deqiang Huang, Xin Xia, Zhengying Wang, Lingyu Luo, Rong Wen

Research output: Contribution to journalArticle

33 Citations (Scopus)

Abstract

Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The "wet" AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF-A) in CNV development has been established and VEGF-A neutralization has become the standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and that CCR3 targeting was reported to be superior to VEGF-A targeting in CNV suppression. We investigated the role of CCR3 in CNV development using the Matrigel induced CNV and found that in both rats and mice, CNV was well-developed in the control eyes as well as in eyes treated with CCR3 antagonist SB328437 or CCR3 neutralizing antibodies. No statistically significant difference in CNV areas was found between the control and SB328437 or CCR3-ab treated eyes. Immunostaining showed no specific expression of CCR3 in or near CNV. In contrast, both VEGF-A neutralizing antibodies and rapamycin significantly suppressed CNV. These results indicate that CCR3 plays no significant role in CNV development and question the therapeutic approach of CCR3 targeting to suppress CNV. On the other hand, our data support the therapeutic strategies of VEGF-A and mTOR (mammalian target of rapamycin) targeting for CNV.

Original languageEnglish
Article numbere17106
JournalPLoS One
Volume6
Issue number2
DOIs
StatePublished - Feb 28 2011

Fingerprint

vascular endothelial growth factor A
Choroidal Neovascularization
angiogenesis
Vascular Endothelial Growth Factor A
Macular Degeneration
eyes
Sirolimus
Neutralizing Antibodies
neutralizing antibodies
therapeutics
blindness
Blindness
Developed Countries
developed countries
neutralization
Rats
antagonists
rats
mice
Therapeutics

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

CCR3 and Choroidal Neovascularization. / Li, Yiwen; Huang, Deqiang; Xia, Xin; Wang, Zhengying; Luo, Lingyu; Wen, Rong.

In: PLoS One, Vol. 6, No. 2, e17106, 28.02.2011.

Research output: Contribution to journalArticle

Li, Y, Huang, D, Xia, X, Wang, Z, Luo, L & Wen, R 2011, 'CCR3 and Choroidal Neovascularization', PLoS One, vol. 6, no. 2, e17106. https://doi.org/10.1371/journal.pone.0017106
Li, Yiwen ; Huang, Deqiang ; Xia, Xin ; Wang, Zhengying ; Luo, Lingyu ; Wen, Rong. / CCR3 and Choroidal Neovascularization. In: PLoS One. 2011 ; Vol. 6, No. 2.
@article{ad982af5355747938e54bd0f16e8f4c2,
title = "CCR3 and Choroidal Neovascularization",
abstract = "Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The {"}wet{"} AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF-A) in CNV development has been established and VEGF-A neutralization has become the standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and that CCR3 targeting was reported to be superior to VEGF-A targeting in CNV suppression. We investigated the role of CCR3 in CNV development using the Matrigel induced CNV and found that in both rats and mice, CNV was well-developed in the control eyes as well as in eyes treated with CCR3 antagonist SB328437 or CCR3 neutralizing antibodies. No statistically significant difference in CNV areas was found between the control and SB328437 or CCR3-ab treated eyes. Immunostaining showed no specific expression of CCR3 in or near CNV. In contrast, both VEGF-A neutralizing antibodies and rapamycin significantly suppressed CNV. These results indicate that CCR3 plays no significant role in CNV development and question the therapeutic approach of CCR3 targeting to suppress CNV. On the other hand, our data support the therapeutic strategies of VEGF-A and mTOR (mammalian target of rapamycin) targeting for CNV.",
author = "Yiwen Li and Deqiang Huang and Xin Xia and Zhengying Wang and Lingyu Luo and Rong Wen",
year = "2011",
month = "2",
day = "28",
doi = "10.1371/journal.pone.0017106",
language = "English",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - CCR3 and Choroidal Neovascularization

AU - Li, Yiwen

AU - Huang, Deqiang

AU - Xia, Xin

AU - Wang, Zhengying

AU - Luo, Lingyu

AU - Wen, Rong

PY - 2011/2/28

Y1 - 2011/2/28

N2 - Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The "wet" AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF-A) in CNV development has been established and VEGF-A neutralization has become the standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and that CCR3 targeting was reported to be superior to VEGF-A targeting in CNV suppression. We investigated the role of CCR3 in CNV development using the Matrigel induced CNV and found that in both rats and mice, CNV was well-developed in the control eyes as well as in eyes treated with CCR3 antagonist SB328437 or CCR3 neutralizing antibodies. No statistically significant difference in CNV areas was found between the control and SB328437 or CCR3-ab treated eyes. Immunostaining showed no specific expression of CCR3 in or near CNV. In contrast, both VEGF-A neutralizing antibodies and rapamycin significantly suppressed CNV. These results indicate that CCR3 plays no significant role in CNV development and question the therapeutic approach of CCR3 targeting to suppress CNV. On the other hand, our data support the therapeutic strategies of VEGF-A and mTOR (mammalian target of rapamycin) targeting for CNV.

AB - Age-related macular degeneration (AMD) is the leading cause of irreversible blindness in the elderly in industrialized countries. The "wet" AMD, characterized by the development of choroidal neovacularization (CNV), could result in rapid and severe loss of central vision. The critical role of vascular endothelial growth factor A (VEGF-A) in CNV development has been established and VEGF-A neutralization has become the standard care for wet AMD. Recently, CCR3 was reported to play an important role in CNV development and that CCR3 targeting was reported to be superior to VEGF-A targeting in CNV suppression. We investigated the role of CCR3 in CNV development using the Matrigel induced CNV and found that in both rats and mice, CNV was well-developed in the control eyes as well as in eyes treated with CCR3 antagonist SB328437 or CCR3 neutralizing antibodies. No statistically significant difference in CNV areas was found between the control and SB328437 or CCR3-ab treated eyes. Immunostaining showed no specific expression of CCR3 in or near CNV. In contrast, both VEGF-A neutralizing antibodies and rapamycin significantly suppressed CNV. These results indicate that CCR3 plays no significant role in CNV development and question the therapeutic approach of CCR3 targeting to suppress CNV. On the other hand, our data support the therapeutic strategies of VEGF-A and mTOR (mammalian target of rapamycin) targeting for CNV.

UR - http://www.scopus.com/inward/record.url?scp=79951899224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79951899224&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0017106

DO - 10.1371/journal.pone.0017106

M3 - Article

C2 - 21358803

AN - SCOPUS:79951899224

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e17106

ER -